CN107252441A - It is a kind of to treat pharmaceutical composition of mastadenitis of cow and preparation method thereof - Google Patents
It is a kind of to treat pharmaceutical composition of mastadenitis of cow and preparation method thereof Download PDFInfo
- Publication number
- CN107252441A CN107252441A CN201710689196.3A CN201710689196A CN107252441A CN 107252441 A CN107252441 A CN 107252441A CN 201710689196 A CN201710689196 A CN 201710689196A CN 107252441 A CN107252441 A CN 107252441A
- Authority
- CN
- China
- Prior art keywords
- cow
- pharmaceutical composition
- mastadenitis
- weighed
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Alternative & Traditional Medicine (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition for treating mastadenitis of cow and preparation method thereof, said composition is prepared from by the raw material of following mass percent：Origanum oil 0.2%~12%；Eugenol 0.05%~6%；Acetic acid chlorhexidine 0.05%~0.5%；Surfactant 0.9%~48%；Cosurfactant 0.3%~16%；Distilled water 17.5%~98.5%；The total weight percent of above-mentioned raw materials is 100%.The present invention is compounded from Chinese herbal medicine extract origanum oil, eugenol and chemicals acetic acid chlorhexidine, nanoemulsion is prepared into, particle diameter is between 1~100nm, and outward appearance is transparency liquid, can infinite dilution, mastadenitis of cow, nonreactive, noresidue can be treated by breast perfusion, toxic side effect is few or nothing, it is easy to use, safety, efficiently.
Description
Technical field
The present invention relates to herding field, and in particular to a kind of pharmaceutical composition for treating mastadenitis of cow and its preparation side
Method.
Background technology
Mastadenitis of cow is one of three big important diseases of milk cow.In the global annual economic damage caused by mastitis for milk cows
Lose and reach multi-million dollar, while also influence milk output and its quality of dairy produce.For a long time, mastadenitis of cow is generally adopted
Treated with antibiotics, although effectively, but a large amount of of such medicine use, and easily produce drug resistance and form antibiosis
Plain milk, potential hazard is caused to human health.
Nano-emulsion (nanoemulsion) be by water, oil, surfactant and cosurfactant etc. by a certain percentage from
Thermodynamically stable, isotropic transparent or semitransparent homogeneous dispersion system that hair is formed, that particle diameter is 1~100nm.Receive
Rice milk is divided into two kinds of oil-in-water type (O/W) and water-in-oil type (W/O).Wherein oil-in-water (O/W) type nano-emulsion granularity is small, hydrophily
Good, unit liquid is containing granule number is more, be uniformly dispersed, stability height；Degree of absorbing is high, and insoluble drug release is rapid, can pass through epithelium
Cytoplasm is directly entered blood circulation；The solubility of poorly water soluble drugs can be improved, medicine that is insoluble and being insoluble in water is realized
It can be administered with molten water.
Origanum oil (Oregano oil), is a kind of volatile oil extracted from natural plant " wild marjoram ", is a kind of new
Animal health medicine.Its main component has quinone, dipentene, coriandrol and perfume (or spice) in carvacrol, thymol, thymol, stone
Schizonepeta phenol etc..The wherein phenolic compound such as carvacrol has stronger antibacterial activity, can readily penetrate through the cell membrane of pathogenic microorganism,
Change its structure, destroy its eubolism function；And Intramitochondrial breathing oxidizing process can be effectively prevented, make the micro- life of cause of disease
Thing loses energy and dead, the function with stronger suppression and killing multiple pathogenic microorganisms, and will not produce drug resistance.
Eugenol (Eugenol) is plant clove of myrtaceae (Syxygium aromaticum (L.) Merr.Et Perry) volatile oil
In Main Ingredients and Appearance, pharmacological research shows that eugenol has the pharmacological activity such as antipyretic, analgesia, anti-inflammatory, anti-oxidant.Eugenol has
There is significant mosquito effect of dispelling, its fungistatic effect significantly, has the effect of sterilizing and itch-relieving, and smell to the local skin of bite by mosquitos
Fragrance, Transdermal absorption effect is strong, is worth exploitation, promotion and application.Acetic acid chlorhexidine (Chlorhexidine) also known as acetic acid are washed must
Thailand, is a kind of white or off-white color crystalline powder, is slightly soluble in water, is soluble in ethanol.Allow to use for animal food, but be not required to
Formulate the medicine of residue limits.The medical instrument has great broad-spectrum antibacterial, bactericidal action, is a kind of preferable sterilizing
Medicine, it is stronger than disinfectants such as bromogeramines to the antibacterial action of Gram-positive and negative bacterium, deposited even in having serum, blood etc.
When it is still effective.Origanum oil, eugenol, acetic acid chlorhexidine are fat-soluble medicine, and nano-emulsion is made after being compounded, adds
The solubility of medicine, the nano-emulsion particle diameter of preparation is small, Thermodynamically stable, good hydrophilic property, and insoluble drug release is rapid, can be thin by epithelium
Matrix is directly entered blood circulation.In addition, origanum oil, eugenol and acetic acid chlorhexidine are respectively provided with antibacterial, sterilization, anti-inflammatory work
With wherein eugenol also has local anesthetic action, and use in conjunction can not only kill the various pathogens for causing mastitis, additionally it is possible to slow
Solution mastitis suffers from the pain of ox, so as to improve the therapeutic effect of clinical mastitis.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition for treating mastadenitis of cow and preparation method thereof, from
Herb extracts origanum oil, eugenol and chemicals acetic acid chlorhexidine are compounded, and are prepared into nanoemulsion, particle diameter 1~
Between 100nm, outward appearance is transparency liquid, can infinite dilution, mastadenitis of cow, nonreactive, without residual can be treated by breast perfusion
Stay, toxic side effect is few or nothing, easy to use, safety, efficiently.
To achieve the above object, the technical scheme taken of the present invention is：
A kind of pharmaceutical composition for treating mastadenitis of cow, is prepared from by the raw material of following mass percent：
Preferably, above-mentioned raw materials are pharmaceutical grade, food-grade or feed grade raw material.
Preferably, described surfactant is APEO (40) rilanit special (RH40), APEO
(40) one kind in castor oil (EL40) and Tween-80.
Preferably, described cosurfactant is one kind in ethanol, propane diols, 1,3-BDO.
Present invention also offers a kind of preparation method for the pharmaceutical composition for treating mastadenitis of cow, comprise the following steps：
S1, by above-mentioned formula weigh each raw material；
S2, at normal temperatures and pressures, by the origanum oil weighed, eugenol it is well mixed after, obtain oil phase；
S3, the surfactant weighed is added into gained oil phase, after mixing, obtain mixed liquor A；
S4, the acetic acid chlorhexidine weighed is added in weighed cosurfactant, stirring dissolves it, then will
It is added in the mixed liquor A of gained, is stirred, is obtained mixed liquid B；
S5, by the distilled water weighed be slowly added to gained mixed liquid B in, it is stirring while adding, until formed nanoemulsion,
Produce.
Nanoemulsion outward appearance obtained by the present invention is light yellow transparent liquid, liquid-drop diameter size between 1~100nm,
After distilled water diluting, breast perfusion can be carried out to mastitis milk cow is suffered from, 2 times a day, 3 days are 1 course for the treatment of, and 2 courses for the treatment of are used in conjunction,
Mastitis caused by various pathogens effectively being prevented and treated, makes to suffer from ox symptom and substantially mitigates, and milk recovers normal, output of milk increase.
The invention has the advantages that：
Preparation method is simple, and storage is stable, is diluted with water water/oil phase and does not separate；Liquid droplet size is small, is that transparency liquid can nothing
Limit dilution, breast perfusion facilitates medication；Good hydrophilic property, is uniformly dispersed, and stability is high, and bioavilability can be improved than conventional dosage forms
30%, individual is reduced using difference；Diffusivity is good, and energy instantaneous dispersing is uniform in cold water, and particulate is close to hydrone, the coupling with water
Power is extremely strong, can produce high dissolving diffusivity；Compared with conventional medicament, bioavailability of the present invention is high, nonreactive noresidue, poison
Few side effects or nothing, easy to use, safety, efficiently.The present invention can effectively treat mastadenitis of cow caused by various pathogens.
Brief description of the drawings
Fig. 1 is the electromicroscopic photograph (scale of compound wild marjoram oil nanometer emulsion in the embodiment of the present invention：200nm).
Fig. 2 is the particle diameter distribution (quantity particle diameter distribution) of compound origanum oil nanoemulsion in the embodiment of the present invention.
Fig. 3 is the particle diameter distribution (density particle diameter distribution) of compound origanum oil nanoemulsion in the embodiment of the present invention.
Embodiment
In order that objects and advantages of the present invention are more clearly understood, the present invention is carried out with reference to embodiments further
Describe in detail.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, it is not used to limit this hair
It is bright.
Embodiment 1
S1, at normal temperatures and pressures, after 6g origanum oils, 3g eugenols are mixed, stirs, is used as oil phase；
S2, into oil phase add 33g Tween-80s as surfactant, stir, obtain mixed liquor A；
S3, take 0.25g acetic acid chlorhexidine add 9g ethanol in, stirring dissolve it, be then added into gained mixing
Stirred in liquid A；
S4,48.75g distilled water is slowly added in above-mentioned mixed liquor, stirring while adding, system viscosity is smaller during beginning,
With the addition of dampening, system can become sticky, continue to be added dropwise and be stirred continuously, until forming nanoemulsion, produce the present invention.
By the present invention with after 5 times of distilled water diluting, breast perfusion can be carried out to milk cow, can effectively prevent and treat various pathogens and draw
The mastitis risen, makes to give milk and is recovered, and reduces economic loss, improves milk cattle cultivating benefit.
Embodiment 2
S1, at normal temperatures and pressures, after 12g origanum oils, 6g eugenols are mixed, stirs, is used as oil phase；
S2, into oil phase add 48g Tween-80s as surfactant, stir, obtain mixed liquor A；
S3, take 0.5g acetic acid chlorhexidine add 16g ethanol in, stirring dissolve it, be then added into gained mixing
In liquid A, stir；
S4,17.5g distilled water is slowly added in said mixture, stirring while adding, system viscosity is smaller during beginning, with
The addition of dampening, system can become sticky, continue to be added dropwise and be stirred continuously, until forming nanoemulsion, produce the present invention.
By the present invention with after 10 times of distilled water diluting, breast perfusion can be carried out to milk cow, can effectively prevent and treat various pathogens
Caused mastitis, makes to give milk and is recovered, and reduces economic loss, improves milk cattle cultivating benefit.
Embodiment 3
S1, at normal temperatures and pressures, after 0.2g origanum oils, 0.05g eugenols are mixed, stirs, is used as oil phase；
S2, into oil phase add 0.9g Tween-80s as surfactant, stir, obtain mixture A；
S3, take 0.05g acetic acid chlorhexidine add 0.3g ethanol in, stirring dissolve it, be then added into gained
In mixed liquor A, stir；
S4,98.5g distilled water is slowly added in said mixture, stirring while adding, system viscosity is smaller during beginning, with
The addition of dampening, system can become sticky, continue to be added dropwise and be stirred continuously, until forming nanoemulsion, produce the present invention.
The present invention directly can suffer from Niu Jinhang breast perfusions to suffer from recessive mastitis, can effectively prevent and treat various pathogens and cause
Mastitis, make to give milk and recovered, reduce economic loss, improve milk cattle cultivating benefit.
Embodiment 4
Test medicine：Prepared sample in embodiment 1；
Animal subject：The case that selection lactation period suffers from clinical mastitis carries out clinical test.Milk cow's milk area occurs following
Symptom or partial symptoms person, diagnosable is clinical mastitis：1. breast volume increase, heating, quality are hardened；2. skin of breast
Rubescent, palpation has pain；③Ge Ru areas are not of uniform size, supramammary lymph node enlargement；4. milk discoloration, it is sticky, occur floccule,
Ziega, clot etc. are abnormal.Accordingly, finally make a definite diagnosis out and suffer from the Gong860Ge Ru areas morbidity of clinic mastitis newborn area.By 860 breasts
Area is randomly divided into 4 groups, per Zu215Ge Ru areas.1. high dose group of the present invention, 216 Ge Ru areas, use the sample prepared in embodiment 1
Product stoste is treated.2. middle dose group of the present invention, 214 Ge Ru areas, are treated using 5 times of dilutions of the sample prepared in embodiment 1.③
Low dose group of the present invention, 213 Ge Ru areas are treated using 10 times of dilutions of the sample prepared in embodiment 1.4. control group, 218
Newborn area, is treated using penicillin and streptomycin.
Test method：First the indoor milk of ill breast is extracted, is sterilized after nipple, is noted using milk duct with 75% cotton ball soaked in alcohol
Enter method.1. high dose group of the present invention, the sample stoste that will be prepared by the method for embodiment 1, once inject 50ml, then gently massage
Breast, morning and afternoon, respectively once 2 courses for the treatment of were used in conjunction in 3 days as one therapeutic course.2. middle dose group of the present invention, will be by the method system of embodiment 1
Standby sample carries out 5 times of dilutions with distilled water, once injects 50ml, then gently massaging breasts, and morning and afternoon once, 3 days is respectively
One course for the treatment of, is used in conjunction 2 courses for the treatment of.3. low dose group of the present invention, 10 times are carried out by the sample prepared by the method for embodiment 1 with distilled water
Dilution, once injects 50ml, then gently massaging breasts, and morning and afternoon, respectively once 2 courses for the treatment of were used in conjunction in 3 days as one therapeutic course.4. it is right
According to group, with the unit of penicillin 800,000, plus streptomysin 1g, it is dissolved in 50ml aqua sterilisas, once injects 50ml, then gently massage lotion
Room, morning and afternoon, respectively once 2 courses for the treatment of were used in conjunction in 3 days as one therapeutic course.
Curative effect is divided into according to clinical symptoms, lactation etc. after treatment：
1) cure：Breast red and swollen heat pain disappears, milk outward appearance is normal, recover normal lactation；
2) effectively：Breast inflammation substantially mitigates, milk outward appearance is normal, the output of milk substantially increases；
3) it is invalid：Milk outward appearance and the output of milk can not recover normal after the treatment of two courses for the treatment of, preceding without much with treatment
Change person.
Result of the test：The present invention is shown in Table 1 to the therapeutic effect of milk cow clinical mastitis.As a result show：Height of the invention,
In, low dose group and control group treatment clinical mastitis cure rate be respectively 94.9%, 92.52%, 50.7% and
63.76%, total effective rate is respectively 100%, 95.32%, 64.79% and 78.44%.At the statistics softwares of SPSS 11.5
Reason, using χ2Testing significance of difference.As a result show, high dose group and middle dose group of the present invention are to milk cow clinic mastitis
Cure rate difference is not notable (P ＞ 0.05), total effective rate significant difference (P ＜ 0.05)；The high, cure rate of middle dose group and always have
Efficiency is compared with low dose group respectively, and inequality heteropole is significantly (P ＜ 0.01)；The high, cure rate of middle dose group and mycillin group
Between inequality heteropole significantly (P ＜ 0.01), the total effective rate difference of high dose group and mycillin group extremely significantly (P ＜ 0.01),
The total effective rate significant difference (P ＜ 0.05) of middle dose group and mycillin group；The cure rate of low dose group and mycillin group
Compare, significant difference (P ＜ 0.05), but total effective rate difference is not notable (P ＞ 0.05).Result of the test shows, the present invention is high, in
The therapeutic effect to milk cow clinic mastitis of dosage is significantly better than low dose group and control group (P ＜ 0.05).
The present invention treatment milk cow clinic mastitis effect of table 1
Described above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (5)
1. a kind of pharmaceutical composition for treating mastadenitis of cow, it is characterised in that prepared by the raw material of following mass percent and
Into：
2. a kind of pharmaceutical composition for treating mastadenitis of cow as claimed in claim 1, it is characterised in that above-mentioned raw materials are
Pharmaceutical grade, food-grade or feed grade raw material.
3. a kind of pharmaceutical composition for treating mastadenitis of cow as claimed in claim 1, it is characterised in that live on described surface
Property agent be APEO (40) rilanit special (RH40), APEO (40) castor oil (EL40) and Tween-80 in
It is a kind of.
4. a kind of pharmaceutical composition for treating mastadenitis of cow as claimed in claim 1, it is characterised in that described helps surface
Activating agent is one kind in ethanol, propane diols, 1,3-BDO.
5. a kind of preparation method for the pharmaceutical composition for treating mastadenitis of cow, it is characterised in that comprise the following steps：
S1, the formula as described in claim any one of 1-3 weigh each raw material；
S2, at normal temperatures and pressures, by the origanum oil weighed, eugenol it is well mixed after, obtain oil phase；
S3, the surfactant weighed is added into gained oil phase, after mixing, obtain mixed liquor A；
S4, the chlorhexidine acetate weighed is added in weighed cosurfactant, stirring dissolves it, is then added
Enter into the mixed liquor A of gained, stir, obtain mixed liquid B；
S5, by the distilled water weighed be slowly added to gained mixed liquid B in, it is stirring while adding, until formed nanoemulsion, i.e.,
.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710689196.3A CN107252441A (en) | 2017-08-07 | 2017-08-07 | It is a kind of to treat pharmaceutical composition of mastadenitis of cow and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710689196.3A CN107252441A (en) | 2017-08-07 | 2017-08-07 | It is a kind of to treat pharmaceutical composition of mastadenitis of cow and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107252441A true CN107252441A (en) | 2017-10-17 |
Family
ID=60026815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710689196.3A Pending CN107252441A (en) | 2017-08-07 | 2017-08-07 | It is a kind of to treat pharmaceutical composition of mastadenitis of cow and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107252441A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111494461A (en) * | 2020-04-26 | 2020-08-07 | 咸阳职业技术学院 | Nanoemulsion for preventing and treating canine skin diseases and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1761486A (en) * | 2003-03-20 | 2006-04-19 | 法马西亚公司 | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| WO2014137231A3 (en) * | 2013-03-07 | 2014-12-31 | T2G Biotechnology Limited | Totarol extract formulations and uses thereof |
| CN104288222A (en) * | 2014-10-16 | 2015-01-21 | 咸阳职业技术学院 | Nano-medicine for treating dairy cow endometritis and preparation method of nano-medicine |
| CN105560374A (en) * | 2016-01-26 | 2016-05-11 | 中国农业科学院兰州畜牧与兽药研究所 | Compound preparation for treating dairy cow mammitis and preparation method thereof |
-
2017
- 2017-08-07 CN CN201710689196.3A patent/CN107252441A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1761486A (en) * | 2003-03-20 | 2006-04-19 | 法马西亚公司 | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| WO2014137231A3 (en) * | 2013-03-07 | 2014-12-31 | T2G Biotechnology Limited | Totarol extract formulations and uses thereof |
| CN104288222A (en) * | 2014-10-16 | 2015-01-21 | 咸阳职业技术学院 | Nano-medicine for treating dairy cow endometritis and preparation method of nano-medicine |
| CN105560374A (en) * | 2016-01-26 | 2016-05-11 | 中国农业科学院兰州畜牧与兽药研究所 | Compound preparation for treating dairy cow mammitis and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 布日额: "《乳源致病性无乳链球菌表面蛋白研究》", 31 December 2016, 黑龙江大学出版社 * |
| 陈百万等: "丁香精油抗奶牛乳腺炎病原微生物活性研究", 《绵阳师范学院学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111494461A (en) * | 2020-04-26 | 2020-08-07 | 咸阳职业技术学院 | Nanoemulsion for preventing and treating canine skin diseases and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1709398B (en) | Filtering-degerming Chinese medicine or animal-plant volatile oil or fat emulsion and preparing method | |
| CN100512835C (en) | Chinese herbal medicine slow release agent for preventing and treating rabbit and chicken coccidiosis and preparing method thereof | |
| CN102716168B (en) | Rifaximin-containing preparation for preventing and treating dairy cow mastitis during dry period and method for preparing rifaximin-containing preparation | |
| US20210007360A1 (en) | Solutions comprising ozonized oil | |
| CN101822631B (en) | Combination drug for repelling animals and insects | |
| CN105853454A (en) | Broad-spectrum antiparasitic drug nano-emulsion and preparation method thereof | |
| CN106511267A (en) | Compound moxidectin drops as well as preparation method and application thereof | |
| CN1045384C (en) | Method for producing effective beriberi distillate "Once Effeclive" "Beriberi Annihilated" | |
| CN105434786A (en) | Milk cow hoof bath lotion and preparation method thereof | |
| CN104288222B (en) | A kind of Nano medication for treating cow endometritis and preparation method thereof | |
| JP2009269904A (en) | Herbal medicinal composition for curing external wound and bedsore and method of manufacturing medicine from the composition | |
| CN107252441A (en) | It is a kind of to treat pharmaceutical composition of mastadenitis of cow and preparation method thereof | |
| CN112043817A (en) | Anti-mite composition and application thereof | |
| CN101947258B (en) | Film-spraying agent for treating bovine mastitis | |
| KR20100025958A (en) | Medical's a composite of the calf | |
| CN103721138B (en) | A kind of traditional Chinese medicine for external application and its preparation method treating rosacea | |
| CN103070951B (en) | Externally used medicinal composition for treating cattle mange and preparation method thereof | |
| CN103251691B (en) | Chinese medicine formula for treating bovine mastitis as well as extract and preparation thereof | |
| CN103006681A (en) | Compound emulsifiable paste for treating acne and preparation method thereof | |
| CN1047080C (en) | Process for preparing medicine to inhibit skin itch | |
| CN105982882B (en) | A kind of externally applied drug and preparation process of optical active starting materials composition prescription therapeutic hemorrhoid | |
| CN106577838A (en) | Preparation method of mosquito repellent liquid based on ten Chinese herbal medicines | |
| CN105832764A (en) | Ointment for treating eczema mammae and preparation method of ointment | |
| CN106237029A (en) | A kind of aloe antibiotic gel and preparation method thereof | |
| CN109453146A (en) | Composition of resisting pathogenic microbes and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171017 |